Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 2/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | RET | P07949 | 7/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.52 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29614915 | 1.00 | KDM4E (0.58) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL29614840 | 0.92 | RET (0.65) | KDM4ERETMKNK1MKNK2NPC1 | |
| SCHEMBL19307094 | 0.92 | RET (0.65) | KDM4ERETMKNK1MKNK2NPC1 | |
| SCHEMBL29614786 | 0.90 | MKNK1 (0.61) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL19307076 | 0.90 | MKNK1 (0.61) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL19307177 | 0.78 | ALDH1A1 (0.74) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL29614816 | 0.76 | KDM4E (0.64) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL19307179 | 0.76 | KDM4E (0.64) | KDM4EALDH1A1HPGDHSD17B10POLB | |
| SCHEMBL29614725 | 0.75 | ABL1 (0.52) | RET | |
| SCHEMBL19307127 | 0.75 | ABL1 (0.52) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | CORNELL UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | CORNELL UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
| US-20210238167-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2021-08-05 | — | — | US | disclosed |
| US-10988461-B2 | Small molecule IRE1-α inhibitors | CORNELL UNIVERSITY (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988461-B2 | Small molecule IRE1-α inhibitors | CORNELL UNIVERSITY (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190016706-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2019-01-17 | — | — | US | disclosed |
| US-20190016706-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2019-01-17 | — | — | US | disclosed |
| US-10125123-B2 | Small molecule IRE1-α inhibitors | CORNELL UNIVERSITY (US) | 2018-11-13 | — | — | US | disclosed |
| US-20170253590-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2017-09-07 | — | — | US | disclosed |
| US-20170253590-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2017-09-07 | — | — | US | disclosed |
| US-20170253590-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016706-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | XBP1, ERN1, ERN2 | KDM4E 3444/4885ALDH1A1 4022/4885HPGD 2994/4885 |
| US-10125123-B2 | Small molecule IRE1-α inhibitors | XBP1, ERN1, ERN2 | KDM4E 3437/4885ALDH1A1 3996/4885HPGD 2997/4885 |
| US-20170253590-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | XBP1, ERN1, ERN2 | KDM4E 3444/4885ALDH1A1 4022/4885HPGD 2994/4885 |
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | PTGES, PTGS1, PTGES2 | KDM4E 3937/4885ALDH1A1 901/4885HPGD 14/4885 |
| US-10988461-B2 | Small molecule IRE1-α inhibitors | XBP1, ERN1, ERN2 | KDM4E 3437/4885ALDH1A1 3996/4885HPGD 2997/4885 |
| US-20210238167-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | XBP1, ERN1, ERN2 | KDM4E 3444/4885ALDH1A1 4022/4885HPGD 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.